Patients with relapsed and refractory follicular lymphoma who had received at least 1 prior anti-CD20–containing chemoimmunotherapy regimen enrolled in GO29834, a phase 1b/2 study.
These patients were aged 62 years (median), mostly male (59%), and had advanced stage follicular lymphoma (88%). Most (77%) had received 2 or more prior lines of therapy, and half (50%) did not respond to their last treatment. At the time of the primary data analysis, a total of 56 patients were enrolled in the study, and median duration of patient follow-up was 12 months.
All patients reported at least 1 side effect with the Pola-G-Len regimen. More than half (55%) experienced a serious side effect. The most common severe side effects were neutropenia (55%), thrombocytopenia (27%), infections (20%), and anemia (14%). One-quarter of patients (25%) had a side effect that led to the discontinuation of 1 or more study drugs.
Among 46 patients for whom the efficacy of Pola-G-Len could be assessed, the objective response rate was 76%. The rate of complete response was 63%. About two-thirds (68%) of patients who were refractory to their last treatment achieved a complete or partial response after treatment with Pola-G-Len.
Researchers concluded that this study of triplet combination Pola-G-Len demonstrates a safety profile that is consistent with what is known about the individual drugs. Rates of complete response were quite high in this heavily pretreated and refractory group of patients. The regimen’s effectiveness compares well with currently available treatments for relapsed and refractory follicular lymphoma. Experts believe that these findings support further study of the Pola-G-Len combination in follicular lymphoma.
Abstract 126. ASH 2019.
Learn more about our family of publications.
View Our Publications